JAZZ News and Press, Jazz Pharmaceuticals plc From 06/02/23

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers PR Newswire Results presented today at ASCO 2023 and concurrently published in The Lancet Oncology demonstrate meanin...

2023-05-31 10:45:37 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – May 31, 2023 – USA News Group –  With this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days ...

Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023 PR Newswire Seven abstracts emphasize Jazz's commitment to advancing the care and understanding of debilitating sleep disorders such as narcolepsy and idiopathic ...

Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare Conference PR Newswire DUBLIN , May 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 Goldman Sachs Global...

Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023 PR Newswire Zanidatamab data to be featured in oral presentation at ASCO 2023 Webcast to follow on June 2, 2023 at 6:45 p.m. CT DUBLIN , May 25, 2023 /PRNewswire/ ...

2023-05-25 07:20:06 ET One investment theme that captured the market’s imagination over the past decade but has been out of favor over recent years and thus might be […] For further details see: Time to Revisit the CBD Growth Theme? (JAZZ, MRES, SNDL, CRON, VFF, YCBD, HEXO...

2023-05-14 23:25:14 ET Summary Seth Klarman’s 13F portfolio value decreased from $6.13B to $5.85B this quarter. Baupost Group increased Alphabet and Fidelity National Information Services while dropping Meta Platforms, Micron Technology, and Amazon.com. The portfolio co...

2023-05-10 20:49:06 ET Jazz Pharmaceuticals PLC (JAZZ) Q1 2023 Earnings Conference Call May 10, 2023, 16:30 ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Co-Founder, Chairman & CEO Daniel Swisher - President & COO Robert Iann...

2023-05-10 16:12:33 ET Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q1 Non-GAAP EPS of $3.95 misses by $0.27 . Revenue of $892.8M (+9.7% Y/Y) misses by $5.25M . FY23 Outlook: Revenue of $3675M-$3875M vs $3.79B consensus For further details se...

Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance PR Newswire Focus on commercial execution drove 1Q23 total revenues of $892.8 million Continued adoption of Xywav ® ; net product sales increased 49% ...